29 November 2012

Abcodia, a UCL spin out company with investment from UCLB, has been shortlisted in three categories for the Startups Awards 2012.

Abcodia is the world leader in biomarker validation and discovery for cancer screening. As well as securing exclusive access to the largest blood serum biobank of its kind, Abcodia, has established its position in supporting the development of new biomarkers that can transform the cancer screening market.

Abcodia is one of 35 companies from across the country that has been named as a finalist, and winners will be announced at a ceremony at the Kensington Roof Gardens, London on 7 December 2012.

The company has been shortlisted for the Angel or VC-backed Business of the Year and Innovative Business of the Year.

Abcodia’s CEO, Dr Julie Barnes, who has also been shortlisted for Start-up Business Woman of the Year, said she was thrilled that Abcodia’s pioneering work had achieved such high profile recognition, saying: “Our passion is to improve the way cancer is diagnosed. By harnessing the best of technology and innovative clinical designs using our unique collection of longitudinal and pre-diagnosis serum, we are convinced that we can develop better blood-based tests for early diagnosis and screening. I am delighted that this work is already being recognized through these prestigious awards and being a finalist is a testament to the dedication shown by our team.

The full shortlist is available online; please visit: www.startupsawards.co.uk to see the complete list of finalists.

About Abcodia
Abcodia is a specialist company engaged in the validation and discovery of biomarkers of cancer and other age-related diseases. The company’s prospective biobank has over 5,000,000 serum samples derived from more than 200,000 initially healthy volunteers, 50,000 of whom have provided samples annually, making this an ideal resource for identifying biomarkers for disease screening. Abcodia was spun out from UCL with investment from UCLB. Abcodia has been granted rights to commercialise IP from one of the largest biobanks in the UK which has been created by lead clinical scientists at UCL, one of the world’s leading research-led universities.

For further information please see: www.abcodia.com

About UCLB
UCLB is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities.

UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from the laboratory to market.

UCLB supports UCL’s Grand Challenges of increasing UCL’s positive impact on and contribution to Global Health, Sustainable Cities, Intercultural Interaction and Human Wellbeing.

For further information, please visit: www.uclb.com